Pembrolizumab Protocol for Metastatic Triple-Negative Breast Cancer (PD-L1 CPS ≥10%)
For first-line treatment of metastatic triple-negative breast cancer with PD-L1 CPS ≥10%, administer pembrolizumab 200 mg IV every 3 weeks in combination with chemotherapy (nab-paclitaxel, paclitaxel, or gemcitabine-carboplatin), continuing pembrolizumab until disease progression, unacceptable toxicity, or for a maximum of 24 months (approximately 35 cycles). 1, 2
Dosing Regimen
Pembrolizumab Dosing
- Standard dose: 200 mg IV every 3 weeks 1, 3, 2
- Alternative dose: 400 mg IV every 6 weeks (FDA-approved extended-interval dosing) 1
- Recent real-world data demonstrates equivalent safety and efficacy with extended-interval dosing in breast cancer patients 4
- Extended-interval dosing reduces treatment burden without compromising outcomes
Chemotherapy Options (Investigator's Choice)
Select ONE of the following regimens 3, 2:
- Nab-paclitaxel (most commonly used in trials)
- Paclitaxel
- Gemcitabine plus carboplatin
Pembrolizumab should be administered prior to chemotherapy on Day 1 of each cycle 3.
Treatment Duration
- Maximum pembrolizumab duration: 24 months (approximately 35 cycles) 1, 3
- Chemotherapy duration: Platinum agents may be administered for 6 or more cycles per local guidelines 1
- Continue until: RECIST v1.1-defined disease progression, unacceptable toxicity, or completion of maximum duration 3
Efficacy Data Supporting This Protocol
The KEYNOTE-355 trial established this as standard of care 3, 2:
- Progression-free survival in CPS ≥10 population: 9.7 months (pembrolizumab-chemotherapy) vs 5.6 months (placebo-chemotherapy); HR 0.65, p=0.0012 3
- Overall survival in CPS ≥10 population: 23.0 months vs 16.1 months; HR 0.73, p=0.0185 2
- Objective response rate: 30-66.7% depending on patient characteristics 5, 6
Critical point: The treatment effect increases with PD-L1 enrichment. Patients with CPS <10 did not demonstrate significant benefit and this combination is not FDA-approved for that population 1, 3, 2.
PD-L1 Testing Requirement
- Mandatory: PD-L1 expression must be determined using an FDA-approved test before initiating therapy 1
- Threshold: CPS ≥10 required for FDA approval in metastatic setting 1
- Testing method: PD-L1 IHC 22C3 pharmDx™ kit (used in KEYNOTE-355) 3
Safety Considerations
Expected Adverse Events
- Grade 3-5 treatment-related adverse events: 68% (similar to chemotherapy alone at 67%) 3, 2
- Immune-related adverse events: 22.7% pooled incidence 6
- Treatment-related deaths: <1% 3
Important Caveat for Extended-Interval Dosing
While grade 3+ immune-related adverse events were lower with extended-interval dosing in early-stage disease (4% vs 20%, p=0.01), this finding requires cautious interpretation as most patients in this analysis switched to extended-interval after initial standard-interval therapy 4.
Clinical Pearls
Predictors of better response 5, 6:
- Absence of liver metastases (ORR 45.5% without liver mets)
- PD-L1-positive status (ORR 66.7% in highly positive tumors)
- First-line therapy (superior to ≥second-line)
Duration of response: Among responders, 80% maintained response >12 months, with some responses continuing even after treatment discontinuation 5.
Quality of life: No significant deterioration in patient-reported outcomes compared to chemotherapy alone, supporting tolerability of this regimen 7.
Contraindications
Patients ineligible for this protocol 3:
- Autoimmune disease requiring systemic therapy within 2 years
- Medical conditions requiring immunosuppression
- PD-L1 CPS <10 (not FDA-approved for metastatic setting)